Skip to main content
Top
Published in:

Open Access 22-09-2023 | Insulins | Practical Approach

Simplification of Complex Insulin Regimens with IdegLira in People with Type 2 Diabetes: Literature Review and Clinical Recommendations

Authors: C. Builes-Montaño, E. Wandurraga, A. Ramírez, J. E. Ordóñez

Published in: Diabetes Therapy | Issue 11/2023

Login to get access

Abstract

Introduction

This study developed a simple algorithm based on clinical results described in medical literature and which allows one to simplify complex insulin regimes with IdegLira to avoid adverse events related to the complexity of some insulin treatments.

Methods

We conducted a systematic review of the literature that allowed us to identify studies that evaluated the clinical result of simplifying complex insulin regimes. The authors reviewed the common factors these simpler regimes had, including the type of patients who used them.

Results

We found nine clinical studies published between 2017 and 2022, eight performed in Europe and one in Latin America. The monitoring time of the studies ranged between 3 and 18 months. The size of the study populations was between 61 and 611 patients (the latter was in five countries). In all studies, HbA1c decreased by 0.6–1.7% and the weight decreased by 0.1–3.11 kg.

Conclusions

On the basis of the findings of these studies, we made some recommendations for clinical practice to simplify treatment. The results of these studies support an algorithm that simplifies the treatment of complex insulin regimens.
Literature
1.
go back to reference Munshi MN, Slyne C, Segal AR, Saul N, Lyons C, Weinger K. Simplification of insulin regimen in older adults and risk of hypoglycemia. JAMA Intern Med. 2016;176(7):1023–5.PubMedCrossRef Munshi MN, Slyne C, Segal AR, Saul N, Lyons C, Weinger K. Simplification of insulin regimen in older adults and risk of hypoglycemia. JAMA Intern Med. 2016;176(7):1023–5.PubMedCrossRef
2.
go back to reference Sofra D. Glycemic control in a real-life setting in patients with type 2 diabetes treated with IDegLira at a single Swiss center. Diabetes Ther. 2017;8(2):377–84.PubMedPubMedCentralCrossRef Sofra D. Glycemic control in a real-life setting in patients with type 2 diabetes treated with IDegLira at a single Swiss center. Diabetes Ther. 2017;8(2):377–84.PubMedPubMedCentralCrossRef
3.
go back to reference Price H, Blüher M, Prager R, et al. Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: results from a European, multicentre, retrospective chart review study. Diabetes Obes Metab. 2018;20(4):954–62.PubMedPubMedCentralCrossRef Price H, Blüher M, Prager R, et al. Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: results from a European, multicentre, retrospective chart review study. Diabetes Obes Metab. 2018;20(4):954–62.PubMedPubMedCentralCrossRef
4.
go back to reference Miya A, Nakamura A, Miyoshi H, et al. Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: a randomized controlled trial. J Diabetes Investig. 2018;9(1):119–26.PubMedCrossRef Miya A, Nakamura A, Miyoshi H, et al. Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: a randomized controlled trial. J Diabetes Investig. 2018;9(1):119–26.PubMedCrossRef
5.
go back to reference Taybani Z, Bótyik B, Katkó M, Gyimesi A, Várkonyi T. Simplifying complex insulin regimens while preserving good glycemic control in type 2 diabetes. Diabetes Ther. 2019;10(5):1869–78.PubMedPubMedCentralCrossRef Taybani Z, Bótyik B, Katkó M, Gyimesi A, Várkonyi T. Simplifying complex insulin regimens while preserving good glycemic control in type 2 diabetes. Diabetes Ther. 2019;10(5):1869–78.PubMedPubMedCentralCrossRef
7.
go back to reference Di Loreto C, Celleno R, Piastrella L, Del Sindaco P. IDegLira fixed-ratio combination in the real world: a retrospective observational single-center Italian experience. Eur Rev Med Pharmacol Sci. 2020;24(20):10671–9.PubMed Di Loreto C, Celleno R, Piastrella L, Del Sindaco P. IDegLira fixed-ratio combination in the real world: a retrospective observational single-center Italian experience. Eur Rev Med Pharmacol Sci. 2020;24(20):10671–9.PubMed
8.
go back to reference Harris S, Abrahamson MJ, Ceriello A, et al. Clinical considerations when initiating and titrating insulin degludec/liraglutide (IDegLira) in people with type 2 diabetes. Drugs. 2020;80(2):147–65.PubMedPubMedCentralCrossRef Harris S, Abrahamson MJ, Ceriello A, et al. Clinical considerations when initiating and titrating insulin degludec/liraglutide (IDegLira) in people with type 2 diabetes. Drugs. 2020;80(2):147–65.PubMedPubMedCentralCrossRef
9.
go back to reference Rosenstock J, Nino A, Soffer J, et al. Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial. Diabetes Care. 2020;43(10):2509–18.PubMedPubMedCentralCrossRef Rosenstock J, Nino A, Soffer J, et al. Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial. Diabetes Care. 2020;43(10):2509–18.PubMedPubMedCentralCrossRef
11.
go back to reference Naing S, Ramesh G, Garcha J, Poliyedath A, Khandelwal S, Mills PK. Is the stepping-down approach a better option than multiple daily injections in obese patients with poorly controlled type 2 diabetes on advanced insulin therapy? Endocrinol Diabetes Metab. 2020;4(2):e00204.PubMedPubMedCentralCrossRef Naing S, Ramesh G, Garcha J, Poliyedath A, Khandelwal S, Mills PK. Is the stepping-down approach a better option than multiple daily injections in obese patients with poorly controlled type 2 diabetes on advanced insulin therapy? Endocrinol Diabetes Metab. 2020;4(2):e00204.PubMedPubMedCentralCrossRef
12.
go back to reference Giugliano D, Longo M, Caruso P, et al. Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized. Pragmatic Trial Diabetes Care. 2021;44(6):1353–60.PubMedCrossRef Giugliano D, Longo M, Caruso P, et al. Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized. Pragmatic Trial Diabetes Care. 2021;44(6):1353–60.PubMedCrossRef
13.
go back to reference Persano M, Nollino L, Sambataro M, et al. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy. Eur Rev Med Pharmacol Sci. 2021;25(2):923–31.PubMed Persano M, Nollino L, Sambataro M, et al. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy. Eur Rev Med Pharmacol Sci. 2021;25(2):923–31.PubMed
14.
go back to reference Zenari L, Da Porto A, De Moliner L, et al. Real-world evaluation of glycemic outcomes and extra-glycemic parameters in diabetic patients treated with the combined formulation degludec-liraglutide (Ideglira). Diabetes Ther. 2021;12(1):197–209.PubMedCrossRef Zenari L, Da Porto A, De Moliner L, et al. Real-world evaluation of glycemic outcomes and extra-glycemic parameters in diabetic patients treated with the combined formulation degludec-liraglutide (Ideglira). Diabetes Ther. 2021;12(1):197–209.PubMedCrossRef
15.
go back to reference Boggild MK, Cheung AM. Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c n T2DM. Ann Intern Med. 2021;174(9):JC106.PubMedCrossRef Boggild MK, Cheung AM. Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c n T2DM. Ann Intern Med. 2021;174(9):JC106.PubMedCrossRef
16.
go back to reference Böhm AK, Schneider U, Aberle J, Stargardt T. Regimen simplification and medication adherence: fixed-dose versus loose-dose combination therapy for type 2 diabetes. PLoS ONE. 2021;16(5):e0250993.PubMedPubMedCentralCrossRef Böhm AK, Schneider U, Aberle J, Stargardt T. Regimen simplification and medication adherence: fixed-dose versus loose-dose combination therapy for type 2 diabetes. PLoS ONE. 2021;16(5):e0250993.PubMedPubMedCentralCrossRef
17.
go back to reference Sancho-Mestre C, Vivas-Consuelo D, Alvis-Estrada L, et al. Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data. BMC Health Serv Res. 2016;16(1):394.PubMedPubMedCentralCrossRef Sancho-Mestre C, Vivas-Consuelo D, Alvis-Estrada L, et al. Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data. BMC Health Serv Res. 2016;16(1):394.PubMedPubMedCentralCrossRef
18.
go back to reference Weng W, Liang Y, Kimball ES, et al. Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis. J Med Econ. 2016;19(7):655–62.PubMedCrossRef Weng W, Liang Y, Kimball ES, et al. Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis. J Med Econ. 2016;19(7):655–62.PubMedCrossRef
19.
go back to reference Cannon AJ, Bargiota A, Billings L, et al. Evaluation of the short-term cost-effectiveness of IDegLira versus basal insulin and basal-bolus therapy in patients with type 2 diabetes based on attainment of clinically relevant treatment targets. J Manag Care Spec Pharm. 2020;26(2):143–53.PubMed Cannon AJ, Bargiota A, Billings L, et al. Evaluation of the short-term cost-effectiveness of IDegLira versus basal insulin and basal-bolus therapy in patients with type 2 diabetes based on attainment of clinically relevant treatment targets. J Manag Care Spec Pharm. 2020;26(2):143–53.PubMed
20.
go back to reference Raya PM, Blasco FJA, Hunt B, et al. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence. Diabetes Obes Metab. 2019;21(6):1349–56.PubMedPubMedCentralCrossRef Raya PM, Blasco FJA, Hunt B, et al. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence. Diabetes Obes Metab. 2019;21(6):1349–56.PubMedPubMedCentralCrossRef
21.
go back to reference American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125–43.CrossRef American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125–43.CrossRef
22.
go back to reference Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221–8 (Erratum in Diabetologia. 2020 Aug;63(8):1667).PubMedCrossRef Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221–8 (Erratum in Diabetologia. 2020 Aug;63(8):1667).PubMedCrossRef
23.
go back to reference Diabetes Canada Clinical Practice Guidelines Expert Committeee, Lipscombe L, Butalia S, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 UPDATE. Can J Diabetes. 2020;44(7):575–91.CrossRef Diabetes Canada Clinical Practice Guidelines Expert Committeee, Lipscombe L, Butalia S, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 UPDATE. Can J Diabetes. 2020;44(7):575–91.CrossRef
25.
go back to reference The Royal Australian College of General Practitioners. Management of type 2 diabetes: a handbook for general practice. East Melbourne, Vic: RACGP, 2020. The Royal Australian College of General Practitioners. Management of type 2 diabetes: a handbook for general practice. East Melbourne, Vic: RACGP, 2020.
26.
go back to reference Ministerio de Salud y Protección Social, departamento administrativo de Ciencia, tecnología e innovación – Colciencias. Guía de práctica clínica para el diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años. Bogotá D.C.: Minsalud, 2016. Ministerio de Salud y Protección Social, departamento administrativo de Ciencia, tecnología e innovación – Colciencias. Guía de práctica clínica para el diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años. Bogotá D.C.: Minsalud, 2016.
27.
go back to reference ElSayed NA, Aleppo G, American Diabetes Association, et al. 9 pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–57.PubMedCrossRef ElSayed NA, Aleppo G, American Diabetes Association, et al. 9 pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–57.PubMedCrossRef
28.
go back to reference Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;1(2):100–7.PubMedPubMedCentralCrossRef Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;1(2):100–7.PubMedPubMedCentralCrossRef
29.
go back to reference von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–9.CrossRef von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–9.CrossRef
30.
go back to reference Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372):n71.CrossRef Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372):n71.CrossRef
31.
go back to reference Makam AN, Nguyen OK. An evidence-based medicine approach to antihyperglycemic therapy in diabetes mellitus to overcome overtreatment. Circulation. 2017;135(2):180–95.PubMedPubMedCentralCrossRef Makam AN, Nguyen OK. An evidence-based medicine approach to antihyperglycemic therapy in diabetes mellitus to overcome overtreatment. Circulation. 2017;135(2):180–95.PubMedPubMedCentralCrossRef
32.
go back to reference Lega IC, Campitelli MA, Austin PC, et al. Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study. Diabetologia. 2021;64(5):1093–102.PubMedCrossRef Lega IC, Campitelli MA, Austin PC, et al. Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study. Diabetologia. 2021;64(5):1093–102.PubMedCrossRef
33.
go back to reference Al-Musawe L, Torre C, Guerreiro JP, et al. Overtreatment and undertreatment in a sample of elderly people with diabetes. Int J Clin Pract. 2021;75(11):e14847.PubMedCrossRef Al-Musawe L, Torre C, Guerreiro JP, et al. Overtreatment and undertreatment in a sample of elderly people with diabetes. Int J Clin Pract. 2021;75(11):e14847.PubMedCrossRef
34.
go back to reference Giugliano D, Scappaticcio L, Longo M, et al. Simplification of complex insulin therapy: a story of dogma and therapeutic resignation. Diabetes Res Clin Pract. 2021;178:108958.PubMedCrossRef Giugliano D, Scappaticcio L, Longo M, et al. Simplification of complex insulin therapy: a story of dogma and therapeutic resignation. Diabetes Res Clin Pract. 2021;178:108958.PubMedCrossRef
36.
go back to reference Cowart K, Updike WH, Pathak R. Prevalence of and characteristics associated with overbasalization among patients with type 2 diabetes using basal insulin: a cross-sectional study. Clin Diabetes. 2021;39(2):173–5.PubMedPubMedCentralCrossRef Cowart K, Updike WH, Pathak R. Prevalence of and characteristics associated with overbasalization among patients with type 2 diabetes using basal insulin: a cross-sectional study. Clin Diabetes. 2021;39(2):173–5.PubMedPubMedCentralCrossRef
37.
go back to reference Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20(10):1512–7.PubMedCrossRef Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20(10):1512–7.PubMedCrossRef
38.
go back to reference Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14(2):71–5.PubMed Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14(2):71–5.PubMed
39.
go back to reference Giugliano D, Maiorino MI, Bellastella G, Esposito K. Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes. J Endocrinol Invest. 2019;42(5):495–503.PubMedCrossRef Giugliano D, Maiorino MI, Bellastella G, Esposito K. Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes. J Endocrinol Invest. 2019;42(5):495–503.PubMedCrossRef
40.
go back to reference Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med. 2012;29(7):e13–20.PubMedCrossRef Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med. 2012;29(7):e13–20.PubMedCrossRef
41.
go back to reference Guyton J, Jeon M, Brooks A. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. Am J Health Syst Pharm. 2019;76(21):1739–48.PubMedCrossRef Guyton J, Jeon M, Brooks A. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. Am J Health Syst Pharm. 2019;76(21):1739–48.PubMedCrossRef
42.
go back to reference Ramírez-Rincón A, Builes-Montaño CE, Hincapié-García JA, Blanco VM, Botero-Arango JF. Short-term effectiveness and reduction in insulin requirements in patients with type 2 diabetes treated with IdegLira in a real-world setting. Front Endocrinol (Lausanne). 2022;28(13): 828607.CrossRef Ramírez-Rincón A, Builes-Montaño CE, Hincapié-García JA, Blanco VM, Botero-Arango JF. Short-term effectiveness and reduction in insulin requirements in patients with type 2 diabetes treated with IdegLira in a real-world setting. Front Endocrinol (Lausanne). 2022;28(13): 828607.CrossRef
43.
go back to reference Kuhtreiber WM, Washer SL, Hsu E, et al. Low levels of C-peptide have clinical significance for established type 1 diabetes. Diabet Med. 2015;32(10):1346–53.PubMedPubMedCentralCrossRef Kuhtreiber WM, Washer SL, Hsu E, et al. Low levels of C-peptide have clinical significance for established type 1 diabetes. Diabet Med. 2015;32(10):1346–53.PubMedPubMedCentralCrossRef
44.
go back to reference Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21–22 october 2001. Diabetes. 2004;53(1):250–64.PubMedCrossRef Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21–22 october 2001. Diabetes. 2004;53(1):250–64.PubMedCrossRef
45.
go back to reference Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG. Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabet Med. 2016;33(11):1554–8.PubMedPubMedCentralCrossRef Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG. Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabet Med. 2016;33(11):1554–8.PubMedPubMedCentralCrossRef
46.
go back to reference Gjessing HJ, Matzen LE, Faber OK, Frøland A. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia. 1989;32(5):305–11.PubMedCrossRef Gjessing HJ, Matzen LE, Faber OK, Frøland A. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia. 1989;32(5):305–11.PubMedCrossRef
47.
go back to reference Jones AG, McDonald TJ, Shields BM, et al. Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care. 2016;39(2):250–7.PubMedCrossRef Jones AG, McDonald TJ, Shields BM, et al. Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care. 2016;39(2):250–7.PubMedCrossRef
48.
go back to reference Lingvay I, Harris S, Jaeckel E, Chandarana K, Ranthe MF, Jódar E. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. Diabetes Obes Metab. 2018;20(1):200–5.PubMedCrossRef Lingvay I, Harris S, Jaeckel E, Chandarana K, Ranthe MF, Jódar E. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. Diabetes Obes Metab. 2018;20(1):200–5.PubMedCrossRef
49.
go back to reference Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care. 2018;41(5):1009–16.PubMedCrossRef Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care. 2018;41(5):1009–16.PubMedCrossRef
50.
go back to reference Aroda VR, González-Galvez G, Grøn R, et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):596–605.PubMedCrossRef Aroda VR, González-Galvez G, Grøn R, et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):596–605.PubMedCrossRef
51.
go back to reference Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885–93.PubMedCrossRef Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885–93.PubMedCrossRef
52.
go back to reference Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90.PubMedPubMedCentralCrossRef Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90.PubMedPubMedCentralCrossRef
53.
go back to reference Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN basal-bolus type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489–97.PubMedCrossRef Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN basal-bolus type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489–97.PubMedCrossRef
54.
go back to reference Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN basal-bolus type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–507.PubMedCrossRef Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN basal-bolus type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–507.PubMedCrossRef
55.
go back to reference Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464–71.PubMedPubMedCentralCrossRef Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464–71.PubMedPubMedCentralCrossRef
56.
go back to reference Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98(3):1154–62.PubMedPubMedCentralCrossRef Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98(3):1154–62.PubMedPubMedCentralCrossRef
57.
go back to reference Fadini GP, Buzzetti R, Fittipaldi MR, et al. IDegLira for the real-world treatment of type 2 diabetes in Italy: protocol and interim results from the REX observational study. Diabetes Ther. 2022;13(8):1483–97.PubMedPubMedCentralCrossRef Fadini GP, Buzzetti R, Fittipaldi MR, et al. IDegLira for the real-world treatment of type 2 diabetes in Italy: protocol and interim results from the REX observational study. Diabetes Ther. 2022;13(8):1483–97.PubMedPubMedCentralCrossRef
58.
go back to reference American Diabetes Association. 12. Older adults: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S168–79.CrossRef American Diabetes Association. 12. Older adults: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S168–79.CrossRef
Metadata
Title
Simplification of Complex Insulin Regimens with IdegLira in People with Type 2 Diabetes: Literature Review and Clinical Recommendations
Authors
C. Builes-Montaño
E. Wandurraga
A. Ramírez
J. E. Ordóñez
Publication date
22-09-2023
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 11/2023
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-023-01471-9

Other articles of this Issue 11/2023

Diabetes Therapy 11/2023 Go to the issue

A quick guide to ECGs

Electrocardiography Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

Obesity Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more